AMAM – Data Update and Virtual Presentation on ARX788
From the event writeup linked below: Virtual presentation to take place on February 24, 2023 at 12:00pm ET Event will feature discussions regarding ARX788, Ambrx’s proprietary anti-HER2 targeting ADC, from key opinion leaders in breast cancer, Hope S. Rugo, M.D., FASCO, and Paula R. Pohlmann, M.D., M.S., Ph.D. Data update for APEX-01, a first-in-human study […]